Skip to content
    LYFE Capital logo

    LYFE Capital

    SingaporeFounded 2015
    www.lyfecapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    LYFE Capital is a healthcare-focused investment platform founded in 2015, connecting healthcare champions with global markets, supply chains, and strategic partners across Asia and the U.S. The firm invests in critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services, with a portfolio spanning biopharma, medtech, diagnostics, and digital health.

    51% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-b (46% of deals). Average disclosed round size is $87.0M (across 33 rounds with reported amounts).

    Find people at LYFE Capital on Goldilocks AI

    Portfolio

    33

    Fund Size

    $935M

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    Alan Wang

    Alan Wang

    Managing Director

    Frances Chovanec

    Frances Chovanec

    Managing Director

    Peter Lee

    Peter Lee

    Managing Director

    YL

    Yao Li Ho

    Managing Director

    Derek Yuan

    Derek Yuan

    Partner

    Jack Chen

    Jack Chen

    Partner

    James Zhao

    James Zhao

    Founder and Partner

    Sameer Rohatgi

    Sameer Rohatgi

    Partner

    William Chen

    William Chen

    Partner

    Alvin Koh

    Alvin Koh

    Investment Principal and Senior Director, APAC Business Development

    David Liu

    David Liu

    Director of Investor Relations

    Vivien Li

    Vivien Li

    Director of Business Development

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    39 investments
    CompanyRoundAmountDate
    AAspen NeuroscienceSeries C$115MNov 2025
    Starna Therapeutics logoStarna TherapeuticsSeries B$44MOct 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Gem Health logoGem HealthSeries A$7MMar 2025
    Verdiva Bio logoVerdiva BioSeries A$410MJan 2025
    ProfoundBio logoProfoundBioSeries B$112MFeb 2024
    CytoTronics logoCytoTronicsSeed$13.5MJan 2024
    KKyverna TherapeuticsSeries B$60MAug 2023
    Noah Medical logoNoah MedicalSeries B$150MApr 2023
    NNoahmedSeries B$150MJan 2023
    瀚辰光翼 logo瀚辰光翼Unknown—Jan 2023
    Iecure logoIecureSeries A$65MNov 2022
    ProfoundBio logoProfoundBioSeries A$70MJun 2022
    Aspen Neuroscience logoAspen NeuroscienceSeries B$147.5MMay 2022
    MMediLinkSeries B$70MApr 2022
    Molecular Assemblies logoMolecular AssembliesSeries B$25.8MMar 2022
    MMolecular Assemblies, Inc.Series B$25.8MMar 2022
    MMediLink TherapeuticsSeries B$70MMar 2022
    Sciwind logoSciwindSeries C$70MOct 2021
    ProfoundBio logoProfoundBioSeries A$55MJul 2021
    Exegenesis Bio logoExegenesis BioSeries B$50MJun 2021
    AABclonal BiotechnologySeries C$92.9MFeb 2021
    AAbclonalSeries C$92.9MJan 2021
    MobiDrop logoMobiDropUnknown—Jan 2021
    RRecBioSeries C$158MJan 2021
    Page 1 of 2

    Top Co-Investors

    OrbiMed6 shared
    LAV6 shared
    Legend Capital6 shared
    HongShan4 shared
    Loyal Valley Capital4 shared
    Legend Star4 shared
    Lake Bleu Capital4 shared
    RA Capital Management3 shared
    K2VC3 shared
    IDG Capital3 shared
    Sequoia China3 shared
    Sequoia Capital2 shared
    Lifeforce Capital2 shared
    Alexandria Venture Investments2 shared
    S322 shared
    Revelation Partners2 shared
    ARCH Venture Partners2 shared
    Frazier Life Sciences2 shared
    Logos Capital2 shared
    Oriza Ventures2 shared

    Last updated: 8 September 2026